Tumori, Gridelli: "With immunotherapy 27% death risk reduction"
Thus Cesare Gridelli, director of the department of Oncoematology Ao 'Moscati' of Avellino, intervening in connection today in Milan to the meeting 'Tumori,..
- Center-right1
- Agency2
2 agency rewrites / co-publications detected
Summary
Thus Cesare Gridelli, director of the department of Oncoematology Ao 'Moscati' of Avellino, intervening in connection today in Milan to the meeting 'Tumori, beyond the silence of the disease: the value of immunotherapy today'. Adnkronos - "Immunotherapy was first experienced in advanced stages of disease, where it demonstrated important benefits in terms of survival. Tumori, Gridelli: "With immunotherapy 27% death risk reduction.".
Furthermore, This has reduced the number of relapses.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
Thus Cesare Gridelli, director of the department of Oncoematology Ao 'Moscati' of Avellino, intervening in connection today in Milan to the meeting 'Tumori, beyond the silence of the disease: the value of immunotherapy today'
reliability low1/3 sourcesAdnkronos - "Immunotherapy was first experienced in advanced stages of disease, where it demonstrated important benefits in terms of survival.
reliability low1/3 sourcesTumori, Gridelli: "With immunotherapy 27% death risk reduction.".
reliability low1/3 sourcesThis has reduced the number of relapses.
reliability low1/3 sources
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.